Objective: To investigate how changes to the World Anti-Doping Agency (WADA) guidelines on asthma medication requests have impacted the management of asthmatic athletes in Portugal.
INTRODUCTION
Diagnosing asthma in athletes is challenging. Multiple phenotypes of asthma exist, and different underlying mechanisms contribute to etiopathogenesis. 1, 2 Also, alternative diagnoses must be considered, 3 and in athletes, symptoms are poor predictors of this condition. 4 Objective evidence (eg, positive bronchodilator or bronchoprovocation test), thus, is needed to confirm a diagnosis in this setting. 5 The recommendation of the International Olympic Committee Medical Commission (IOC-MC) for Olympic athletes to present objective evidence of asthma before allowing the use of inhaled b 2 -agonists (IBAs), in place since 2002, has facilitated the study of how asthma impacts different sports and has benefited athletes by ensuring better care. In 2009, the World Anti-Doping Agency (WADA) followed the IOC approach, extending it to all other athletes. 6 The WADA guidelines on asthma, however, have changed in recent years. Before 2009, an abbreviated Therapeutic Use Exemption (aTUE), which did not require objective evidence of asthma, accompanied by a physician's report of asthma, was sufficient for requesting permission to use inhaled corticosteroids (ICS) and inhaled formoterol, salbutamol, salmeterol, and terbutaline. In 2009, however, aTUEs were withdrawn and replaced by a Declaration of Use (DoU) for ICS and a full Therapeutic Use Exemption (TUE) requiring objective evidence for the same 4 IBAs. In 2010, the DoU was extended to salbutamol and salmeterol, but the other IBAs still required a TUE.
The aim of this study was to assess the impact of WADA guideline changes on asthma medication requests by Portuguese athletes.
METHODS
We retrospectively analyzed asthma medication requests submitted to the Portuguese Anti-Doping Authority between 2008 and 2010. Athletes older than 16 years who requested permission to use ICS and/or IBAs for more than 3 months were included. Data on respiratory symptoms, medication requested, spirometry, and atopy (at least 1 positive skin prick test or positive specific IgE) were collected. A diagnosis of asthma was based on a positive bronchodilator test or bronchoprovocation test. 5 Exhaled nitric oxide results were converted to personal predicted values using the FeNO Interpretation Aid tool (http://www.enovis.org) and considered increased if above 150% of predicted. Data were expressed as median and range, and categorical variables were compared using the x 2 or Fisher exact test (statistical significance, P , 0.05). Analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, Illinois).
RESULTS
We analyzed requests from 326 athletes [254 males; median age, 24 years (range, 16-62 years)] ( Figure 1 ). The requests were as follows: in 2008, 173 aTUEs were submitted; in 2009 and 2010, 9 and 39 DoU were submitted, respectively; regarding TUEs, the approval rate was 97% (74 of 76) in 2009 and 79% (23/29) in 2010 (P = 0.005). Requests for ICS combined with IBAs were the most frequent. Requests for isolated IBAs increased significantly from 2009 to 2010 (from 9 to 16, P = 0.03). The clinical and diagnostic tests performed are shown in Table 1 and the corresponding results in Table 2 . No tests were reported in 2008 because all the requests submitted in that year were aTUEs.
DISCUSSION
The introduction of mandatory objective criteria for inhaler use (2009) decreased the requests submitted to the Portuguese Anti-Doping Authority by approximately half, suggesting that a large number of athletes were receiving medication based on symptoms only. The relative similarity between the proportion of positive tests in 2009 and 2010 suggests that the more rigorous testing criteria strategy is reliable. We also saw that changes to the WADA guidelines on IBAs in 2010 led to a dramatic decrease in the number of tests performed in Portuguese athletes with asthma.
Our findings clearly show that WADA guidelines have an impact on the care of athletes with documented asthma and influence how respiratory symptoms are managed and treated in these patients. A study that evaluated the impact of IOC-MC rules found that 21% of British Olympic athletes were receiving asthma medication for which there was no clinical indication. 7 In Portugal, changes to the WADA 2009 Prohibited List permitted more rigorous screening of asthmatic athletes, thanks to the implementation of objective criteria for inhaler use. The new requirements also led to the withdrawal of unnecessary medication. It improved athlete's care by investigation of alternative diagnoses.
Constant changes to WADA guidelines, however, jeopardize the achievements made to date and adversely affect the health of asthmatic athletes. Diagnosis of asthma is complex, and lung function, airway inflammation, and hyperresponsiveness tests provide important complementary information that can aid asthma control. 8 Also, the fact that a TUE is necessary for some IBAs while a DoU is sufficient for FIGURE 1. Flow chart showing requests for asthma medication submitted by athletes to the Anti-Doping Authority of Portugal between 2008 and 2010. Notes: a In 2008, only an abbreviated TUE was required for ICS and IBAs salbutamol, salmeterol, formoterol, and terbutaline (ie, no objective testing or approval was required). b In 2009, salbutamol, salmeterol, terbutaline, and formoterol required a full TUE and ICS required a DoU. c In 2010, salbutamol, salmeterol, and ICS required a DoU while terbutaline and formoterol required a full TUE. d Three requests for formoterol (of which 2 were not approved), 2 for terbutaline (of which 1 was not approved), and 1 for indacaterol. e Twenty-one requests for formoterol (of which 3 were not approved) and 2 requests for salbutamol/terbutaline use. ,0.001* others has generated intense debate 9 and led to different management strategies being used in this setting, as evidenced by our study. In 2010, for example, athletes could avoid objective testing by simply applying to use an IBA that required a DoU. Our findings are limited by the retrospective nature of the study and the fact that the data we collected were anonymous. However, we are certain that the decrease in requests observed in 2009 is not due to the fact that athletes were already covered by a previous submission as renewal was yearly at that time. TUEs now last for 4 years and we can therefore be sure that no repetitions occurred in 2010.
Our study contributes to overcoming the paucity of data regarding asthma in Portuguese athletes. Moreover, we have evaluated how changes in WADA guidelines have impacted the clinical management of asthma in this setting. In the 2012 WADA guidelines, unrestricted use of inhaled salbutamol, salmeterol, or formoterol is permitted as long as specified doses are not exceeded. Such a change, however, might lead to an increased use of long-acting IBAs, without ICS. This is a matter of concern as IBAs may mask worsening of airway inflammation; furthermore, airway inflammation might contribute to the downregulation of IBA receptors. 10 Therefore, although the 2012 guidelines may seem fairer and improve access to treatment among asthmatic athletes, they introduce safety issues stemming from the unsupervised use of IBAs. As shown by our study, in the absence of mandatory objective testing for certain asthma medications, athletes may choose not to undergo lung function tests. The risks associated with such a decision should be investigated in new prospective studies.
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